Most surveyed individuals with obesity support lower-cost options for weight maintenance, which would allow better coverage for injectable incretin mimetics for weight management during active weight loss.
Dina H. Griauzde, MD, MSc, DABOM
Advertisement
Articles by Dina H. Griauzde, MD, MSc, DABOM
The high cost of incretin mimetics for weight management limits insurance coverage and potentiates variation in utilization management strategies to control near-term spending.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
3
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
4
Study Finds Flaw in Method for Key Oncology Value-Based Care Model
5